From a therapeutic perspective, CLDN18.2 clinical trials in gastric cancer have focused on IMAB362 (also known as zolbetuximab) is a chimeric antibody that selectively binds to CLDN18.2-expressing tumor cells with minimal off-target effects. The gene discussed is CLDN18; the disease is gastric cancer.